Nigral Dopaminergic Neurons in Dementia with Lewy Bodies
Introduction <table class="infobox infobox-cell">
...
Nigral Dopaminergic Neurons in Dementia with Lewy Bodies
Introduction <table class="infobox infobox-cell">
Nigral dopaminergic neurons in Dementia with Lewy Bodies (DLB) represent a critical neuronal population that undergoes significant degeneration, contributing to the characteristic parkinsonian features observed in approximately 70-80% of DLB patients[@mckeith2020]. The substantia nigra pars compacta (SNc) contains dopaminergic neurons that project to the striatum, forming the nigrostriatal pathway essential for motor control. In DLB, these neurons are affected by Lewy body pathology, leading to motor symptoms that overlap with Parkinson's disease[@kalia2015].
Overview
Mermaid diagram (expand to render)
Dementia with Lewy bodies (DLB) exhibits significant nigral pathology, with dopaminergic neuron loss contributing to the parkinsonian features observed in most patients. The loss of approximately 50-70% of SNc dopaminergic neurons correlates with the severity of motor symptoms and provides a neurobiological basis for the movement abnormalities seen in DLB["@fahn2006"].
Key Features
Neuronal loss : 50-70% reduction in substantia nigra pars compactaLewy bodies : Alpha-synuclein inclusions in surviving neuronsMotor symptoms : Bradykinesia, rigidity, tremor, postural instabilityTherapeutic response : Variable response to dopaminergic medications<!-- taxonomy-enrichment -->
<!-- multi-taxonomy-enrichment -->
Multi-Taxonomy Classification
Taxonomy Database Cross-References
Morphology & Electrophysiology
Morphology : dopaminergic neuron (source: Cell Ontology)Morphology can be inferred from Cell Ontology classification
PanglaoDB Marker Cross-References
External Database Links
[Cell Ontology (CL:0000700)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700)
[OBO Foundry (CL:0000700)](http://purl.obolibrary.org/obo/CL_0000700)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[Human Cell Atlas](https://www.humancellatlas.org/)
[PanglaoDB](https://panglaodb.se/)
Taxonomy & Classification
PanglaoDB Marker Cross-References
External Database Links
[Cell Ontology (CL:0000700)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000700)
[OBO Foundry (CL:0000700)](http://purl.obolibrary.org/obo/CL_0000700)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[PanglaoDB](https://panglaodb.se/)
Neuroanatomy
Substantia Nigra Structure
Nigrostriatal Pathway
Substantia nigra pars compacta → Striatum (caudate + putamen)Motor control : Regulation of movement initiation and executionReward processing : Mesolimbic dopamine pathway involvement
Pathophysiology
Lewy Body Pathology
Alpha-Synuclein Aggregation
Cytosolic inclusions : Lewy bodies and Lewy neuritesNeuronal dysfunction : Impaired axonal transportSynaptic loss : Decreased dopamine releaseMechanisms of Neuronal Death
Mitochondrial dysfunction : Complex I inhibitionOxidative stress : Increased ROS productionNeuroinflammation : Microglial activationAutophagy impairment : Reduced protein clearanceClinical Manifestations
Motor Symptoms
Core Features
Bradykinesia : Slowed movement and reduced spontaneous activityRigidity : Increased muscle tone, cogwheel qualityResting tremor : 4-6 Hz tremor, often asymmetricPostural instability : Impaired balance and fallsGait Abnormalities
Shuffling gait : Short, shuffling stepsFreezing : Transient inability to initiate movementFestination : Rapid, short stepsNon-Motor Symptoms
Cognitive fluctuations : Variable attention and alertnessVisual hallucinations : Early and prominent featureSleep disorders : REM sleep behavior disorderAutonomic dysfunction : Orthostatic hypotensionNeurochemistry
Dopamine Pathways
Neurotransmitter Interactions
Dopamine : Marked reduction in nigrostriatal pathwayAcetylcholine : Cortical cholinergic deficiencySerotonin : Raphe nuclei involvementNorpinephrine : Locus coeruleus degenerationTherapeutic Approaches
Dopaminergic Medications
Levodopa
Efficacy : Moderate improvement in motor symptomsLimitations : May worsen hallucinationsDosing : Often lower than in PD due to sensitivityDopamine Agonists
Pramipexole : May improve motor symptomsRopinirole : Similar efficacy profileSide effects : Hallucinations, impulse control disordersNon-Motor Symptom Management
Cholinesterase inhibitors : For cognitive symptomsClonazepam : REM sleep behavior disorderMidodrine : Orthostatic hypotensionEmerging Therapies
Alpha-synuclein immunotherapy : Disease modificationNeuroprotective agents : Neurotrophic factorsGene therapy : AAV-based dopamine restorationResearch Directions
Biomarkers
DaTscan : Dopamine transporter imagingCSF biomarkers : Alpha-synuclein speciesMRI : SNc iron depositionClinical Trials
Immunotherapy : Active and passive vaccinationAggregation inhibitors : Small molecule approachesCell replacement : Stem cell therapySee Also
[DLB](/diseases/dementia-lewy-bodies)
[Parkinson's Disease](/diseases/parkinsons-disease)
[/cell-types/dementia-lewy-bodies-neurons](/cell-types/neurons)
[/cell-types/cholinergic-neurons-dementia-lewy-bodies](/cell-types/neurons)
[/cell-types/locus-coeruleus-neurons-dementia-lewy-bodies](/cell-types/neurons)
[Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathology)
[DLB Biomarkers](/biomarkers/dementia-lewy-bodies-biomarkers)
External Links
[Parkinson's Disease - NINDS](https://www.ninds.nih.gov/health-information/disorders/parkinsons-disease) - NIH information
[Lewy Body Dementia Association](https://www.lbda.org/) - Patient resources
[Michael J. Fox Foundation](https://www.michaeljfox.org/) - Research funding
Show full description